Inactive Instrument

RHINOMED

Equities

RNO

AU000000RNO1

RNO: Rhinomed Receives $280k Research And Development Tax Refund

March 15, 2017 at 09:10 pm EDT

RHINOMED RECEIVES $280k RESEARCH AND DEVELOPMENT TAX REFUND March 15th, 2017. Melbourne, Australia.

Respiratory technology company Rhinomed Limited (ASX: RNO) has today received a Research and Development Tax Incentive refund of $279,859 as part of the Australian Government's Research and Development Incentive Program for the 2016 financial year.

These funds reflect a $621,911 investment in research and development used to advance the Company's sleep and respiratory technology platform, including its INPEAP device for obstructive sleep apnea.

The R&D Tax Incentive is a program jointly administered by the Australian Taxation Office and AusIndustry, under which companies receive a 45% refundable tax offset of expenditures on eligible research and development activities.

Media Enquiries

Michael Johnson, CEO & Managing Director

+61 (03) 8416 0900

mjohnson@rhinomed.global

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is monetising applications of its technology platform in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global

Rhinomed Limited published this content on 15 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 March 2017 01:10:11 UTC.

Original documenthttp://www.rhinomed.global/wp-content/uploads/2017/03/Rhinomed-Receives-280k-Research-And-Development-Tax-Refund.pdf

Public permalinkhttp://www.publicnow.com/view/11E0007923C2E5FB1EC8C95156BDAB465A8DBD2E

Latest news about RHINOMED

Rhinomed Completes Minimum Holding Share Buyback Program	Feb. 01	MT
Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director	Nov. 16	CI
Rhinomed Completes Strategic Review of Operations	23-10-24	MT
Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023	23-10-16	CI
Rhinomed Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Rhinomed Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Rhinomed Limited Announces Supply Agreement with BTNX	23-01-26	CI
Rhinomed Secures AU$3.7 Million Capital Facility	22-12-20	MT
Rhinomed Limited Auditor Raises 'Going Concern' Doubt	22-09-27	CI
Rhinomed Validates Accuracy of Pediatric Nasal Swab	22-09-26	MT
Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids	22-09-26	CI
Rhinomed Limited Announces Board Changes	22-09-07	CI
Rhinomed Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI
Rhinomed Limited Receives First Purchase Order for 250,000 Rhinoswab Juniors	22-08-16	CI
Rhinomed Grows Fiscal Q4, FY22 Revenue	22-07-28	MT
Rhinomed Secures Swab Supply Deal for COVID-19 Rapid Antigen Tests	22-07-18	MT
Rhinomed Limited Announces 24 Month Rhinoswab and Rhinoswab Junior Supply Agreement with SureScreen Australia	22-07-17	CI
Rhinomed Trading Halt Lifts After Completion of $2.5 Million Institutional Entitlement Offer	22-04-11	MT
Rhinomed Enters Two-Year Swab Supply Deal With Canadian Test Kit Manufacturer	22-04-07	MT
Rhinomed Limited Enters into Supply Agreement with BTNX Inc	22-04-06	CI
Rhinomed Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-22	CI
Rhinomed Receives Nearly $304,000 R&D Tax Rebate; Shares Up 4%	22-02-15	MT
Rhinomed Fiscal Q2 Revenue Rises 17% Q-o-Q	22-01-26	MT
Rhinomed's Pediatric Nasal Swab Product Meets Primary Endpoint in Device Trial	21-12-20	MT
Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial	21-12-20	CI

Chart RHINOMED

Duration

Period

More charts

Company Profile

Rhinomed Limited is an Australia-based wearable nasal technology company. The Company is engaged in the research, development and commercialization of consumer and medical devices. The Company's products include Mute, Turbine, Pronto Sleep, Pronto Clear and Rhinoswab. Mute dilates the nasal passages making nasal breathing easier, reducing mouth breathing and helping to breathe more, snore less and sleep better. Turbine is designed to fit comfortably inside the nose and gently open each individual nostril to allow more airflow during sport, physical exertion or focused breathing, such as yoga and meditation. Rhinoswab is a patented comfortable, self-administered nasal swab that provides high-yield sampling and fits existing pathology workflows. Pronto Sleep is a vapor inhaler that gently opens the nose and delivers a soothing blend of four pure essential oils. Its nasal platform envisages multiple applications from simple stenting through to nasal drug delivery and sensor/diagnostics.

Sector

More about the company